siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells
The human EGFR family consists of four type-1 transmembrane tyrosine kinase receptors: HER1 (EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). HER3 can dimerize with EGFR, HER2 and even c-Met and likely plays a central role in the response to EGFR-targeted therapy. Because HER3 lacks significant kinase activity and cannot be inhibited by tyrosine kinase inhibitors, neutralizing antibodies and alternative inhibitors of HER3 have been sought as cancer therapeutics. Here, we describe the stable suppression of HER3 mRNA and protein using siRNA. The inhibition of HER3 expression decreased cell proliferation, suppressed cell cycle progression, induced apoptosis and inhibited cell motility, migration, invasiveness, and soft agar growth. In addition, we found that gefitinib treatment increased the HER3 and HER2 mRNA levels. The administration of various concentrations of gefitinib to HER3-knockdown cells enhanced antitumour activity and sensitivity due to the downregulation of protein phosphorylation via PI3K/AKT and ERK signalling. Our results support the use of combined treatments targeting multiple EGFR receptors, particularly the use of HER3 inhibitors combined with EGFR inhibitors, such as gefitinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 32 vom: 08. Aug., Seite 52584-52593 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan, Heng-Heng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.09.2017 Date Revised 13.11.2018 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.17526 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275532070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275532070 | ||
| 003 | DE-627 | ||
| 005 | 20231225005905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.17526 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0918.xml |
| 035 | |a (DE-627)NLM275532070 | ||
| 035 | |a (NLM)28881753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuan, Heng-Heng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2017 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The human EGFR family consists of four type-1 transmembrane tyrosine kinase receptors: HER1 (EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). HER3 can dimerize with EGFR, HER2 and even c-Met and likely plays a central role in the response to EGFR-targeted therapy. Because HER3 lacks significant kinase activity and cannot be inhibited by tyrosine kinase inhibitors, neutralizing antibodies and alternative inhibitors of HER3 have been sought as cancer therapeutics. Here, we describe the stable suppression of HER3 mRNA and protein using siRNA. The inhibition of HER3 expression decreased cell proliferation, suppressed cell cycle progression, induced apoptosis and inhibited cell motility, migration, invasiveness, and soft agar growth. In addition, we found that gefitinib treatment increased the HER3 and HER2 mRNA levels. The administration of various concentrations of gefitinib to HER3-knockdown cells enhanced antitumour activity and sensitivity due to the downregulation of protein phosphorylation via PI3K/AKT and ERK signalling. Our results support the use of combined treatments targeting multiple EGFR receptors, particularly the use of HER3 inhibitors combined with EGFR inhibitors, such as gefitinib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HER3 | |
| 650 | 4 | |a PI3K/AKT | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a gefitinib | |
| 650 | 4 | |a siRNA | |
| 700 | 1 | |a Yang, Ying-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jian-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yan-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Li-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Jun-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhen-Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Qing-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xiao-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ting-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Xiao-Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 32 vom: 08. Aug., Seite 52584-52593 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:32 |g day:08 |g month:08 |g pages:52584-52593 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.17526 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 32 |b 08 |c 08 |h 52584-52593 | ||